Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Delirium prevention and prediction,Part 2

Trial Profile

Delirium prevention and prediction,Part 2

Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Suvorexant (Primary)
  • Indications Delirium
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Aug 2017 New trial record
    • 01 Aug 2017 Primary endpoint (Incidence of delirium as determined by the DSM-5.) has been met as per the results published in the Journal of Clinical Psychiatry.
    • 01 Aug 2017 Results published in the Journal of Clinical Psychiatry
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top